Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications... Show more
Industry Biotechnology
A.I.dvisor indicates that over the last year, CMVLF has been closely correlated with CLLS. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if CMVLF jumps, then CLLS could also see price increases.
| Ticker / NAME | Correlation To CMVLF | 1D Price Change % | ||
|---|---|---|---|---|
| CMVLF | 100% | N/A | ||
| CLLS - CMVLF | 78% Closely correlated | -0.25% | ||
| ABCZF - CMVLF | 59% Loosely correlated | N/A | ||
| SLN - CMVLF | 41% Loosely correlated | -4.78% | ||
| ALDX - CMVLF | 39% Loosely correlated | +0.78% | ||
| CLGN - CMVLF | 37% Loosely correlated | +3.73% | ||
More | ||||